Uno, cento, mille diabeti
Diabete mellito di tipo 1 e 2 - parte prima

1. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabe- tes Care 2011;34:S62-9. 2. WHO. Use of glycated haemoglobin (HbA1c) in the diagnosis of diabetes mellitus: abbreviated report of a WHO consultation, Jan 14, 2011. 3. DCCT Research Group. The effect of inten- sive treatment of diabetes on the development and progression of longterm complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-86. 4. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood glucose control with sulphonylureas or insulin compared with con- ventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53. 5. International Expert Committee. Interna- tional Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care 2009;32:1327-34. 6. Kilpatrick ES, Bloomgarden ZT, Zimmet PZ. Is haemoglobin A1c a step forward for dia- gnosing diabetes? BMJ 2009;339:b4432. 7. Marchetti F, Tornese G, Faleschini E, Poli F. Diagnosis of diabetes. What about cystic fi- brosis? BMJ 2009;339:b5644. 8. Misra S, Hancock M, Meeran K, Dornhost A, Oliver NS. HbA1c: an old friend in new clothes. Lancet 2011;377:1476-7. 9. Bottazzo GF, Florin-Christensen A, Doniach D. Islet-cell antibodies in diabetes mellitus with autoimmune polyendocrine deficiencies. Lancet 1974;2:1279-83. 10. Palmer JP, Asplin CM, Clemons P, et al. In- sulin antibodies in insulin-dependent diabetics before insulin treatment. Science1983;222: 1337-9. 11. Baekkeskov S, Aanstoot HJ, Christgau S, et al. Identification of the 64K autoantigen in insulin-dependent diabetes as the GABA- synthesizing enzyme glutamic acid decar- boxylase. Nature1990;347:151-6. 12. Rabin DU, Pleasic SM, Shapiro JA, et al. Islet cell antigen 512 is a diabetes-specific islet autoantigen related to protein tyrosine pho- sphatases. J Immunol1994;152:3183. 13. Wenzlau JM, Juhl K, Yu L, et al. The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetes. Proc Natl Acad Sci USA2007;104:17040-5. 14. Bingley PJ, Bonifacio E, Williams AJ, Ge- novese S, Bottazzo GF, Gale EA. Prediction of IDDM in the general population: strategies based on combinations of autoantibodiy markers. Diabetes 1997;46:1701-10. 15. Verge CF, Stenger D, Bonifacio E, et al. Combined use of autoantibodies (IA-2 autoan- tibody, GAD autoantibody, insulin autoanti- body, cytoplasmic islet cell antibodies) in ty- pe 1 diabetes: Combinatorial Islet Autoanti- body Workshop. Diabetes 1998;47:1857-66. 16. Bingley PJ, Bonifacio E, Ziegler AG, Schatz DA, Atkinson MA, Eisenbarth GS. Pro- posed guidelines on screening for risk of type I diabetes. Diabetes Care2001;24:398. 17. Achenbach P, Ziegler AG. Diabetes-related antibodies in euglycemic subjects. Best Pract Res Clin Endocrinol Metab2005;19:101-17. 18. Verge CF, Gianani R, Kawasaki E, et al. Prediction of type I diabetes in first-degree re- latives using a combination of insulin, GAD, and ICA512bdc/IA-2 autoantibodies. Diabetes 1996;45:926-33. 19. Wang J, Miao D, Babu S, et al. Prevalence of autoantibody-negative diabetes is not rare at all ages and increases with older age and obe- sity. J Clin Endocrinol Metab2007;92:88-92. 20. DIAMOND Project Group. Incidence and trends of childhood Type 1 diabetes worldwi- de 1990-1999. Diabet Med 2006;23:857-66. 21. Bruno G, Maule M, Merletti F, et al; RIDI Study Group. Age-period-cohort analysis of 1990-2003 incidence time trends of childhood diabetes in Italy: the RIDI study. Diabetes 2010;59:2281-7. 22. Patterson CC, Dahlquist GG, Gyürüs E, Green A, Soltész G; EURODIAB Study Group. Incidence trends for childhood type 1 diabe- tes in Europe during 1989-2003 and predicted new cases 2005-20: a multicentre prospective registration study. Lancet2009;373:2027-33. 23. Harjutsalo V, Sjöberg L, Tuomilehto J. Ti- me trends in the incidence of type 1 diabetes in Finnish children: a cohort study. Lancet 2008;371:1777-82. 24. Atkinson MA, Maclaren NK. The patho- genesis of insulin dependent diabetes. N Engl J Med1994;33:1428-36. 25. Bartolozzi G, Guglielminelli M. Pediatria. Principi e pratica clinica. Elsevier Masson, 2008:389. 26. Barrett JC, Clayton DG, Concannon P, et al. Genome-wide association study and meta- analysis find that over 40 loci affect risk of ty- pe 1 diabetes. Nat Genet2009;41:703-7. 27. Buzzetti R, Quattrocchi CC,Nisticò L. Dis- secting the genetics of type I diabetes: rele- vance for familial clustering and differences in incidence. Diabetes Metab Rev 1998;14:111-28. 28. Gepts W. Pathologic anatomy of the pan- creas in juvenile diabetes mellitus. Diabetes 1965;14:619-33. 29. Atkinson MA, Eisenbarth GS. Type 1 dia- betes: new perspectives on disease pathoge- nesis and treatment. Lancet 2001;358:221-9. 30. Dahlquist GG, Patterson C, Soltesz G. Pe- rinatal risk factors for childhood type 1 diabe- tes in Europe. The EURODIAB Substudy 2 Study Group. Diabetes Care 1999;22:1698-702. 31. Lombardo F, Valenzise M, Wasniewska M, et al. Two year prospective evaluation of the factors affecting honeymoon frequency and duration in children with insulin dependent diabetes mellitus: the key-role of age at dia- gnosis. Diabetes Nutr Metab2002;15:246-51. 32. The Diabetes Control Complication Trial (DCCT) Research Group. The effect of inten- sive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-86. 33. Pickup J, Mattock M, Kerry S. Glycaemic control with continuous subcutaneous insulin infusion compared with intensive insulin injec- tions in patients with type 1 diabetes: meta- analysis of randomised controlled trials. BMJ 2002;324:705. 34. American Diabetes Association. Nutrition principles and recommendations in diabetes (Position Statement). Diabetes Care 2003;26 (Suppl. 1):S51-S61. 35. Scavone G, Manto A, Pitocco D, et al. Ef- fect of carbohydrate counting and medical nu- tritional therapy on glycaemic control in type 1 diabetic subjects: a pilot study. Diabet Med 2010;27:477-9. 36. Zinman B, Ruderman N, Campaigne BN, Devlin JT, Schneider SH, the American Dia- betes Association. Physical activity/exercise and diabetes (Position Statement). Diabetes Care 2004;27(Suppl. 1):S58-S62. 37. Robertson K, Adolfsson P, Riddell M, Scheiner G, Hanas R. Exercise in children and adolescents with diabetes. Pediatr Diabetes 2009;10(Suppl. 12):154-68. 38. Berger M, Assai JP, Jorgens V. Physical exercise in the diabetic. The importance of un- derstanding endocrine and metabolic respon- ses. Diabetes Metab 1998;6:59-69. 39. Rosenbloom AL, Silverstein JH, Amemiya S, Zeitler P, Klingensmith G. Type 2 diabetes in the child and adolescent. Pediatr Diabetes 2009;10:17-32. 40. Pinhas-Hamiel O, Zeitler P. The global spread of type 2 diabetes mellitus in children and adolescents. J Pediatr2005;146:693-700. 41. Kiess W, Böttner A, Blüher S, Raile K, Gal- ler A, Kapellen TM. Type 2 diabetes mellitus in children and adolescents-the beginning of a renal catastrophe? Nephrol Dial Transplant 2004;19:2693-6. 42. Cerutti F, Iughetti L. Sindrome metabolica e diabete di tipo 2 nell’età evolutiva. Roche Diagnostic2005;38-39. 43. Druet C, Tubiana-Rufi N, Chevenne D, Ri- gal O, Polak M, Levy-Marchal C. Characteri- zation of insulin secretion and resistance in ty- pe 2 diabetes of adolescents. J Clin Endocri- nol Metab 2006;91:401-4. 44. The Writing Group for the SEARCH for Diabetes in Youth Study Group. Incidence ofdiabetes in youth in the United States. JAMA 2007;297:2716-24. 45. Whincup PH, Kaye SJ, Owen CG, et al. Birth weight and risk of type 2 diabetes: a sy- stematic review. JAMA 2008;300:2886-97. 46. Morales A,Rosenbloom AL. Death caused by hyperglycemic hyperosmolar state at the onset of type 2 diabetes. J Pediatr 2004;144: 270-3. 47. Pinhas-Hamiel O, Zeitler P. Acute and ch- ronic complications of type 2 diabetes melli- tus in children and adolescents. Lancet 2007; 369:1823-31. 48. Rosembloom AL. Obesity, insulin resi- stance, beta cell autoimmunity, and the chan- ging clinical epidemiology of childhood dia- betes. Diabetes Care 2003;26:2954-6. 49. Turner R, Stratton I, Horton V, et al; for the UK Prospective Diabetes Study (UKPDS) Group. UKPDS 25: Autoantibodies to islet cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes. Lancet1997;350:1288-93. 50. Aslander-van Vliet E, Smart C, Waldron S. Nutritional management in childhood and adolescent diabetes. ISPAD Clinical Practice Consensus Guidelines 2006-2007. Pediatr Dia- betes 2007;8:323-39. 51. Miller J, Silverstein JH, Rosembloom AL. Type 2 diabetes in the child and adolescent. In: Lifshitz F (Ed). Pediatric Endocrinology, 5th edition, Volume 1. New York: Marcel Dekker, 2007:169-88. 52. Wei JN, Sung FC, Li CY, et al. Low birth weight and high birth weight infants are both at an increased risk to have type 2 diabetes among schoolchildren in Taiwan. Diabetes Care 2003;26:343-8. 53. Jeffery RW. Community programs for obe- sity prevention: The Minnesota Heart Health Program. Obes Res 1995;3(Suppl. 2):283s-288s. 54. Craig M, Hattersley A, Donaghue K. Defi- nition, epidemiology, diagnosis and classifica- tion. ISPAD Clinical Practice Consensus Gui- delines 2006-2007. Pediatr Diabetes 2006;7: 343-51.